Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIVOPOSTOP: Adjuvant Nivolumab + Chemo-radiotherapy in High-risk Resected Head and Neck Squamous Cell Carcinoma
NCT03576417Phase 3Active, not recruiting
- Sponsor
- GORTEC
- Start
- Oct 2018
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Disease-Free Survival at 3 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03576417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576417.